唐佩军, 吴妹英. 加强基础临床研究切实提高我国非结核分枝杆菌病诊治水平[J]. 结核与肺部疾病杂志, 2021, 2(2): 93-97. doi: 10.3969/j.issn.2096-8493.2021.02.001
| [1] |
Whitehead N, Wilson R, Floto RA. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志. doi: 10.1136/thoraxjnl-2017-210927.
doi: 10.1136/thoraxjnl-2017-210927 |
| [2] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020,43(11):918-946. doi: 10.3760/cma.j.cn112147-20200508-00570.
doi: 10.3760/cma.j.cn112147-20200508-00570 |
| [3] |
张亚楠, 段鸿飞. 鸟-胞内分枝杆菌复合群肺病的诊断和治疗进展. 中国防痨杂志, 2017,39(10):1126-1129. doi: 10.3969/j.issn.1000-6621.2017.10.008.
doi: 10.3969/j.issn.1000-6621.2017.10.008 |
| [4] |
刘佳文, 吕红艳, 丁北川, 等. 129株非结核分枝杆菌采用两种分子检测技术行菌种鉴定的结果分析. 中国防痨杂志, 2019. 41(9):999-1004. doi: 10.3969/j.issn.1000-6621.2019.09.015.
doi: 10.3969/j.issn.1000-6621.2019.09.015 |
| [5] |
穆晶, 刘子臣, 张晨, 等. 非结核分枝杆菌肺病的病理学特征及分子病理在其诊断中的价值. 中华病理学杂志, 2020,49(6):562-567. doi: 10.3760/cma.j.cn112151-20191028-00669.
doi: 10.3760/cma.j.cn112151-20191028-00669 |
| [6] |
宋婧, 车南颖. 结核病分子病理学诊断技术临床应用进展. 中国防痨杂志, 2018,40(11):1221-1225. doi: 10.3969/j.issn.1000-6621.2018.11.014.
doi: 10.3969/j.issn.1000-6621.2018.11.014 |
| [7] |
温子禄, 王琳, 王军, 等. 术后标本行分子生物学检测对结核病患者诊疗的价值. 中国防痨杂志, 2018,40(12):1291-1295. doi: 10.3969/j.issn.1000-6621.2018.12.010.
doi: 10.3969/j.issn.1000-6621.2018.12.010 |
| [8] |
邵燕, 陈诚, 竺丽梅. 非结核分枝杆菌疾病的流行病学研究. 江苏预防医学, 2019,30(4):374-377. doi: 10.13668/j.issn.1006-9070.2019.04.006.
doi: 10.13668/j.issn.1006-9070.2019.04.006 |
| [9] |
林建, 林淑芳, 戴志松, 等. 福建省非结核分枝杆菌菌种分布及其流行病学特征初步研究. 中国防痨杂志, 2020,42(5):518-522. doi: 10.3969/j.issn.1000-6621.2020.05.018.
doi: 10.3969/j.issn.1000-6621.2020.05.018 |
| [10] |
潘建华, 石国民, 彭雪峰, 等. 长沙地区2012—2017年非结核分枝杆菌流行状况分析. 国际检验医学杂志, 2018,39(20):2496-2498. doi: 10.3969/j.issn.1673-4130.2018.20.008.
doi: 10.3969/j.issn.1673-4130.2018.20.008 |
| [11] |
沈瑶杰, 刘伟, 金嘉琳, 等. 综合性医院非结核分枝杆菌临床分离株的菌种分布特征分析. 中华传染病杂志, 2017,35(10):580-584. doi: 10.3760/cma.j.issn.1000-6680.2017.10.002.
doi: 10.3760/cma.j.issn.1000-6680.2017.10.002 |
| [12] |
Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med, 2012,185(2):231-232. doi: 10.1164/ajrccm.185.2.231.
doi: 10.1164/ajrccm.185.2.231 URL |
| [13] | Giampaglia CM, Martins MC, Inumaru VT, et al. Evaluation of a rapid differentiation test for the Mycobacterium tuberculosis complex by selective inhibition with rho-nitrobenzoic acid and thiophene-2-carboxylic acid hydrazide. Int J Tuberc Lung Dis, 2005,9(2):206-209. |
| [14] | Agarwal A, Dhole TN, Sharma YK. Evaluation of p-nitro benzoic acid (pnb) inhibition test to differentiate Mycobacterium tuberculosis complex from non-tuberculous mycobacteria using microscopic observation of drug susceptibility (MODS) metho-dology. Indian J Tuberc, 2014,61(3):232-235. |
| [15] | Samlı A, Ilki A. Comparison of MALDI-TOF MS, nucleic acid hybridization and the MPT64 immunochromatographic test for the identification of M.tuberculosis and non-tuberculosis Mycobacterium species. New Microbiol, 2016,39(4):259-263. |
| [16] |
Manu D, Otchere ID, Asante-Poku A, et al. Low sensitivity of the MPT64 identification test to detect lineage 5 of the Mycobacterium tuberculosis complex. J Med Microbiol, 2018,67(12):1718-1727. doi: 10.1099/jmm.0.000846.
doi: 10.1099/jmm.0.000846 URL |
| [17] |
Ustinova VV, Smirnova TG, Sochivko DG, et al. New assay to diagnose and differentiate between Mycobacterium tuberculosis complex and nontuberculous mycobacteria. Tuberculosis (Edinb), 2019,114:17-23. doi: 10.1016/j.tube.2018.10.004.
doi: S1472-9792(18)30136-7 pmid: 30711153 |
| [18] |
Shin S, Yoo IY, Shim HJ, et al. Diagnostic Performance of the GENEDIA MTB/NTM Detection Kit for Detecting Mycobacterium tuberculosis and Nontuberculous Mycobacteria With Sputum Specimens. Ann Lab Med, 2020,40(2):169-173. doi: 10.3343/alm.2020.40.2.169.
doi: 10.3343/alm.2020.40.2.169 URL |
| [19] |
Ng KP, Rukumani DV, Chong J, et al. Identification of Mycobacterium species following growth detection with the BACTEC MGIT 960 system by DNA line probe assay. Int J Mycobacteriol, 2014,3(2):82-87. doi: 10.1016/j.ijmyco.2014.03.005.
doi: 10.1016/j.ijmyco.2014.03.005 URL |
| [20] |
Liu J, Yue J, Yan Z, et al. Performance assessment of the CapitalBio mycobacterium identification array system for identification of mycobacteria. J Clin Microbiol, 2012,50(1):76-80. doi: 10.1128/JCM.00320-11.
doi: 10.1128/JCM.00320-11 URL |
| [21] |
Quan TP, Bawa Z, Foster D, et al. Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. J Clin Microbiol, 2018,56(2):e01480-17. doi: 10.1128/JCM.01480-17.
doi: 10.1128/JCM.01480-17 |
| [22] |
Lee AS, Jelfs P, Sintchenko V, et al. Identification of non-tuberculous mycobacteria: utility of the GenoType Mycobacterium CM/AS assay compared with HPLC and 16S rRNA gene sequencing. J Med Microbiol, 2009,58(Pt 7):900-904. doi: 10.1099/jmm.0.007484-0.
doi: 10.1099/jmm.0.007484-0 URL |
| [23] |
Leyer C, Gregorowicz G, Mougari F, et al. Comparison of Saramis 4.12 and IVD 3.0 Vitek MS Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Mycobacteria from Solid and Liquid Culture Media. J Clin Microbiol, 2017,55(7):2045-2054. doi: 10.1128/JCM.00006-17.
doi: 10.1128/JCM.00006-17 URL |
| [24] |
Lee MR, Chang LY, Ko JC, et al. Nontuberculous mycobacterial lung disease epidemiology in Taiwan: A systematic review. J Formos Med Assoc, 2020,119 Suppl 1: S4-S12. doi: 10.1016/j.jfma.2020.05.019.
doi: 10.1016/j.jfma.2020.05.019 URL |
| [25] |
Kham-Ngam I, Chetchotisakd P, Ananta P, et al. Epidemiology of and risk factors for extrapulmonary nontuberculous mycobacterial infections in Northeast Thailand. PeerJ, 2018,6:e5479. doi: 10.7717/peerj.5479.
doi: 10.7717/peerj.5479 URL |
| [26] |
Wassilew N, Hoffmann H, Andrejak C, et al. Pulmonary Disease Caused by Non-Tuberculous Mycobacteria. Respiration, 2016,91(5):386-402. doi: 10.1159/000445906.
doi: 10.1159/000445906 URL |
| [27] |
Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res, 2020,152(3):185-226. doi: 10.4103/ijmr.IJMR_902_20.
doi: 10.4103/ijmr.IJMR_902_20 URL |
| [28] |
Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med, 2015,36(1):35-41. doi: 10.1016/j.ccm.2014.10.003.
doi: 10.1016/j.ccm.2014.10.003 URL |
| [29] |
Tan Y, Su B, Shu W, et al. Epidemiology of pulmonary disease due to nontuberculous mycobacteria in Southern China, 2013-2016. BMC Pulm Med, 2018,18(1):168. doi: 10.1186/s12890-018-0728-z.
doi: 10.1186/s12890-018-0728-z URL |
| [30] |
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020,56(1):2000535. doi: 10.1183/13993003.00535-2020.
doi: 10.1183/13993003.00535-2020 URL |
| [31] |
中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 非结核分枝杆菌病诊断与治疗专家共识. 中华结核和呼吸杂志, 2012,35(8):572-580. doi: 10.3760/cma.j.issn.1001-0939.2012.08.006.
doi: 10.3760/cma.j.issn.1001-0939.2012.08.006 |
| [32] |
Soni I, De Groote MA, Dasgupta A, et al. Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria. J Med Microbiol, 2016,65(1):1-8. doi: 10.1099/jmm.0.000198.
doi: 10.1099/jmm.0.000198 URL |
| [33] |
Dupont C, Viljoen A, Dubar F, et al. A new piperidinol deriva-tive targeting mycolic acid transport in Mycobacterium abscessus. Mol Microbiol, 2016,101(3):515-529. doi: 10.1111/mmi.13406.
doi: 10.1111/mmi.13406 URL |
| [34] |
Wu ML, Aziz DB, Dartois V, et al. NTM drug discovery: status, gaps and the way forward. Drug Discov Today, 2018,23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001.
doi: 10.1016/j.drudis.2018.04.001 URL |
| [35] |
Shoen C, Benaroch D, Sklaney M, et al. In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria. Antimicrob Agents Chemother, 2019,63(5):e02522-18. doi: 10.1128/AAC.02522-18.
doi: 10.1128/AAC.02522-18 |
| [36] |
Poon YK, La Hoz RM, Hynan LS, et al. Tedizolid vs Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients. Open Forum Infect Dis. 2021,8(4):ofab093. doi: 10.1093/ofid/ofab093.
doi: 10.1093/ofid/ofab093 URL |
| [37] |
Le Run E, Arthur M, Mainardi JL. In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus. Antimicrob Agents Chemother, 2019,63(4):e01915-18. doi: 10.1128/AAC.01915-18.
doi: 10.1128/AAC.01915-18 |
| [38] |
Ratnatunga CN, Lutzky VP, Kupz A, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol, 2020,11:303. doi: 10.3389/fimmu.2020.00303.
doi: 10.3389/fimmu.2020.00303 pmid: 32194556 |
| [39] |
Banaschewski B, Hofmann T. Inhaled Antibiotics for Mycobacterial Lung Disease. Pharmaceutics, 2019,11(7):352. doi: 10.3390/pharmaceutics11070352.
doi: 10.3390/pharmaceutics11070352 URL |
| [40] |
Banaschewski B, Verma D, Pennings LJ, et al. Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections. J Cyst Fibros, 2019,18(5):714-720. doi: 10.1016/j.jcf.2019.05.013.
doi: 10.1016/j.jcf.2019.05.013 |
| [41] |
Kim TS, Choe JH, Kim YJ, et al. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus. Antimicrob Agents Chemother, 2017,61(9):e02752-16. doi: 10.1128/AAC.02752-16.
doi: 10.1128/AAC.02752-16 |
| [42] |
时翠林, 牛广豪, 王霞芳, 等. 耐药结核病治疗药物研究进展. 中华结核和呼吸杂志, 2020,43(1):58-63. doi: 10.3760/cma.j.issn.1001-0939.2020.01.013.
doi: 10.3760/cma.j.issn.1001-0939.2020.01.013 |
| [43] |
Brown-Elliott BA, Philley JV, Griffith DE, et al. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex. Antimicrob Agents Chemother, 2017,61(2):e01798-16. doi: 10.1128/AAC.01798-16.
doi: 10.1128/AAC.01798-16 |
| [44] |
杨松, 王乐乐, 严晓峰, 等. 非结核分枝杆菌病治疗药物研究进展. 中华结核和呼吸杂志, 2021,44(1):44-49. doi: 10.3760/cma.j.cn112147-20200227-00199.
doi: 10.3760/cma.j.cn112147-20200227-00199 |
| [45] |
AlMatar M, Makky EA, Yakıcı G, et al. Antimicrobial peptides as an alternative to anti-tuberculosis drugs. Pharmacol Res, 2018,128:288-305. doi: 10.1016/j.phrs.2017.10.011.
doi: 10.1016/j.phrs.2017.10.011 URL |
| [46] |
Dams D, Briers Y. Enzybiotics: Enzyme-Based Antibacterials as Therapeutics. Adv Exp Med Biol, 2019,1148:233-253. doi: 10.1007/978-981-13-7709-9_11.
doi: 10.1007/978-981-13-7709-9_11 |
| [47] |
Gomes AC, Moreira AC, Mesquita G, et al. Modulation of Iron Metabolism in Response to Infection: Twists for All Tastes. Pharmaceuticals (Basel), 2018,11(3):84. doi: 10.3390/ph11030084.
doi: 10.3390/ph11030084 URL |
| [48] |
Torfs E, Piller T, Cos P, et al. Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy. Int J Mol Sci, 2019,20(12):2868. doi: 10.3390/ijms20122868.
doi: 10.3390/ijms20122868 URL |
| [49] |
Oh J, Park HD, Kim SY, et al. Assessment of Vitamin Status in Patients with Nontuberculous Mycobacterial Pulmonary Disease: Potential Role of Vitamin A as a Risk Factor. Nutrients, 2019,11(2):343. doi: 10.3390/nu11020343.
doi: 10.3390/nu11020343 URL |
| [50] |
Oh J, Shin SH, Choi R, et al. Assessment of 7 trace elements in serum of patients with nontuberculous mycobacterial lung disease. J Trace Elem Med Biol, 2019,53:84-90. doi: 10.1016/j.jtemb.2019.02.004.
doi: 10.1016/j.jtemb.2019.02.004 URL |
| [51] | 唐神结, 高文. 临床结核病学.2版. 北京: 人民卫生出版社, 2019: 1026-1041. |
| [52] |
Larsson LO, Polverino E, Hoefsloot W, et al. Pulmonary disease by non-tuberculous mycobacteria-clinical management, unmet needs and future perspectives. Expert Rev Respir Med, 2017,11(12):977-989. doi: 10.1080/17476348.2017.1386563.
doi: 10.1080/17476348.2017.1386563 |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
京公安网备11010202008787号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
